-0.04 | -0.79%
| Price and Volume | |
|---|---|
| Recent Price | 5.02 |
| 52 Week High | 7.05 |
| 52 Week Low | 3.55 |
| Avg. Daily Vol. (Mil) | 0.40 |
| Beta (3 year) | 3.04 |
| Share Related Items | |
| Mkt Cap (Mil) | 399.20 |
| Shares Out (Mil) | 79.52 |
| Float (Mil) | 56.62 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 8.90 |
| Current Ratio | 9.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 499.00 |
| Price/Book | 4.09 |
| Price/Cash Flow | -8.20 |
| Per Share Data | |
| Earnings | -0.69 |
| Sales | 0.01 |
| Book Value | 1.23 |
| Cash Flow | -0.61 |
| Business Summary | |
|---|---|
| ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. | |
| General Information | |
| 1180 Avenue of the Americas
Suite 2020 New York, NY 10036 |
|
| www.ziopharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 66 | |
| CEO: Dr. Jonathan Lewis,M.D., | |
| Short Interest | |
| Current Month (Mil) | 9.60 |
| Previous Month (Mil) | 9.19 |
| Short Interest Ratio (Days) | 29.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -35.00 |
| Return on Investments | -50.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,427.01 | 1,313.32 | 2,835.87 | 15.98 |
Oil *
103.31
|
|
UP
7.15 |
DOWN
19.10 |
DOWN
1.49 |
DOWN
0.27 |
10 Yr
1.60%
SPDR Gold
151.91
|
|
+0.06%
|
-1.43%
|
-0.05%
|
-1.66%
|
Data delayed 20 minutes |
Connect with TheStreet